Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
about
Oncolytic viruses as anticancer vaccinesEphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse modelSelectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells.In situ adenovirus vaccination engages T effector cells against cancerHomologous recombination-based adenovirus vector system for tumor cell-specific gene delivery.Armed replicating adenoviruses for cancer virotherapy.Evolution of oncolytic viruses: novel strategies for cancer treatment.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Arming oncolytic viruses to leverage antitumor immunity.Oncolytic Immunotherapy for Treatment of Cancer.Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatmentOncolytic viruses: adenoviruses.Oncolytic immunotherapy: unlocking the potential of viruses to help target cancerCdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta.Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model.Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy.Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.
P2860
Q27025600-5B74FDFA-EABE-4C04-85E7-442766F2B8AFQ33924763-1709860B-CC7D-48A8-8050-5ACB923DF676Q34343742-AD89EA5A-EC62-4903-BA76-D5A5580F4DADQ36220624-EE4FAA1F-F170-4EFE-8EA2-BDCD72097652Q36493469-E7B89C12-F6CE-48D0-8A66-39034BED9F7FQ37306292-0F2EF8B4-8379-4E85-AF87-9680F4F49703Q37344472-0D4DD857-EAC6-4A95-AF00-7C1FF6AB0679Q37386616-E8FD4712-C2A8-4E5A-8E3D-752B736B2EE3Q38159802-5F303689-05AA-4055-982C-1480A9E863BFQ38223419-AF6E33C2-E1E7-433E-A0A5-4F2D36F3EB72Q38470166-AB5F72D1-65C9-4EDD-BE97-A14DF3BD36CDQ38848223-E4EA5E57-56D7-4A13-A866-6EB205F0C5B8Q39278465-3073B1CF-C92D-4A99-BEF9-C9FACBB18198Q39432063-1B3F69FE-40C1-450C-B998-F064C0A6B217Q39437344-2C89E5F1-302B-4D39-BFD9-5600BE61C96EQ39535096-74A54D8B-F3A6-4DC8-9942-E777BC6246F3Q39778480-6E1EA9B5-9547-4B45-A55C-AEE59F268CE4Q40250421-D63DE267-918E-4814-9BB4-AD6D31D32FFDQ40327515-2817CB75-32B7-4EFF-9818-B987B7E54F08Q42263453-351511FC-62D0-4778-A71D-B250268E48D3Q48893820-F8C46206-71CE-4B27-9299-677C64D5EFC9Q53809292-2E92F91A-0C12-401E-A7FE-A512FF0CAB65
P2860
Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Assessment of a combined, aden ...... munostimulatory tumor therapy.
@en
Assessment of a combined, aden ...... munostimulatory tumor therapy.
@nl
type
label
Assessment of a combined, aden ...... munostimulatory tumor therapy.
@en
Assessment of a combined, aden ...... munostimulatory tumor therapy.
@nl
prefLabel
Assessment of a combined, aden ...... munostimulatory tumor therapy.
@en
Assessment of a combined, aden ...... munostimulatory tumor therapy.
@nl
P2093
P1433
P1476
Assessment of a combined, aden ...... mmunostimulatory tumor therapy
@en
P2093
André Lieber
Anh-Thu Tieu
Shaoheng Ni
P304
P356
10.1158/0008-5472.CAN-04-3527
P407
P577
2005-05-01T00:00:00Z